HDAC9 and neoplasm: However, as noted above, not all types of tumor cells die under the HDACi treatment, which reduces the potential of these compounds as tumor monotherapy agents and raises the question of finding mechanisms to overcome the resistance of tumor cells to HDAC inhibitors.